Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 30;10(8):e037505.
doi: 10.1136/bmjopen-2020-037505.

Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017

Gulfaraz Khan  1 , Christina Fitzmaurice  2 , Mohsen Naghavi  3 , Luai A Ahmed  4
Affiliations

Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990-2017

Gulfaraz Khan et al. BMJ Open. .

Abstract

Objective: To determine the global and regional burden of Epstein-Barr virus (EBV)-attributed malignancies.

Design: An international comparative study based on the Global Burden of Disease (GBD) Study estimates.

Setting: Global population by age, sex, region, demographic index and time.

Methods and outcome measures: The burden of EBV-attributed Burkitt lymphoma (BL), Hodgkin lymphoma (HL), nasopharyngeal carcinoma (NPC) and gastric carcinoma (GC) was estimated in a two-step process. In the first step, the fraction of each malignancy attributable to EBV was estimated based on published studies; this was then applied to the GBD estimates to determine the global and regional incidence, mortality and disability-adjusted life-years (DALYs) for each malignancy by age, sex, geographical region and social demographic index (SDI) from 1990 to 2017.

Results: The combined global incidence of BL, HL, NPC and GC in 2017 was 1.442 million cases, with over 973 000 deaths. An estimated 265 000 (18%) incident cases and 164 000 (17%) deaths were due to the EBV-attributed fraction. This is an increase of 36% in incidence and 19% in mortality from 1990. In 2017, EBV-attributed malignancies caused 4.604 million DALYs, of which 82% was due to NPC and GC alone. The incidence of both of these malignancies was higher in high and middle-high SDI regions and peaked in adults aged between 50 and 70 years. All four malignancies were more common in males and the highest burden was observed in East Asia.

Conclusions: This study provides comprehensive estimates of the burden of EBV-attributed BL, HL, NPC and GC. The overall burden of EBV-related malignancies is likely to be higher since EBV is aetiologically linked to several other malignancies not included in this analysis. Increasing global population and life expectancy is expected to further raise this burden in the future. The urgency for developing an effective vaccine to prevent these malignancies cannot be overstated.

Keywords: epidemiology; microbiology; oncology; public health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Global burden of (A) incident, (B) deaths and (C) DALYs for EBV-attributed malignancies in 2017 by world regions. DALYs, disability-adjusted life-years; EBV, Epstein-Barr virus.
Figure 2
Figure 2
Global burden of incident (A), deaths (B) and DALYs (C) for EBV-attributed malignancies by gender from 1990 to 2017. BL, Burkitt lymphoma; DALYs, disability-adjusted life-years; EBV, Epstein-Barr virus; GC, gastric carcinoma; HL, Hodgkin lymphoma; NPC, nasopharyngeal carcinoma.
Figure 3
Figure 3
Global burden of incident and deaths of EBV-attributed (A) BL, (B) HL, (C) NPC and (D) GC in 2017 by SDI world regions. BL, Burkitt lymphoma; EBV, Epstein-Barr virus; GC, gastric carcinoma; HL, Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; SDI, social demographic index.
See this image and copyright information in PMC

References

    1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. . Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019;4:1749–68. 10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed
    1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030–44. 10.1002/ijc.21731 - DOI - PubMed
    1. de Martel C, Ferlay J, Franceschi S, et al. . Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607–15. 10.1016/S1470-2045(12)70137-7 - DOI - PubMed
    1. Plummer M, de Martel C, Vignat J, et al. . Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016;4:e609–16. 10.1016/S2214-109X(16)30143-7 - DOI - PubMed
    1. Pagano JS, Blaser M, Buendia M-A, et al. . Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004;14:453–71. 10.1016/j.semcancer.2004.06.009 - DOI - PubMed